The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations

Suzumura, 1999, Protective effect of fluvastatin sodium (XU-62-320), 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro, Biochem Pharmacol, 57, 697, 10.1016/S0006-2952(98)00341-4 Jacotot, 1994, Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French–Dutch fluvastatin study group, Br J Clin Pharmacol, 38, 257, 10.1111/j.1365-2125.1994.tb04350.x Mathew, 2017, Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis, Biomed Pharmacother, 93, 681, 10.1016/j.biopha.2017.06.053 Kowalski, 2006, Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention, J Cardiovasc Pharmacol, 48, 143, 10.1097/01.fjc.0000246150.52382.07 Isaacsohn, 2003, Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia, Clin Ther, 25, 904, 10.1016/S0149-2918(03)80113-3 Olsson, 2001, Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial, Clin Ther, 23, 45, 10.1016/S0149-2918(01)80029-1 Ramsey, 2014, The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update, Clin Pharmacol Ther, 96, 423, 10.1038/clpt.2014.125 Messas, 2017, Pharmacogenetics of lipid-lowering agents: an update review on genotype-dependent effects of HDL-targetingand statin therapies, Curr Atheroscler Rep, 19, 43, 10.1007/s11883-017-0679-5 Kirchheiner, 2003, Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers, Clin Pharmacol Ther, 74, 186, 10.1016/S0009-9236(03)00121-8 Niemi, 2006, SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin, Clin Pharmacol Ther, 80, 356, 10.1016/j.clpt.2006.06.010 Meyer zu Schwabedissen, 2015, Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort, Pharmacogenet Genomics, 25, 8, 10.1097/FPC.0000000000000098 Thompson, 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response, Pharmacogenom J, 5, 352, 10.1038/sj.tpj.6500328 Couvert, 2008, Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy, Pharmacogenomics, 9, 1217, 10.2217/14622416.9.9.1217 Clinical Pharmacogenetics Implementation Consortium. CPIC guidelines. Available at: https://cpicpgx.org/guidelines/. Zhou, 2012, CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers, Arzneimittelforschung, 62, 519, 10.1055/s-0032-1323696 Neuvonen, 2008, Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin, Clin Pharmacokinet, 47, 463, 10.2165/00003088-200847070-00003 Kopplow, 2005, Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells, Mol Pharmacol, 68, 1031, 10.1124/mol.105.014605 Noe, 2007, Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1 and OATP1B3, Drug Metab Dispos, 35, 1308, 10.1124/dmd.106.012930 Pasanen, 2008, Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate, Pharmacogenet Genom, 18, 921, 10.1097/FPC.0b013e32830c1b5f Mirosevic Skvrce, 2013, CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study, Pharmacogenomics, 14, 1419, 10.2217/pgs.13.135 Buzkova, 2012, Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population, Med Sci Monit, 18, CR512 Barilla, 2004, Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, lescol xL, Biopharm Drug Dispos, 25, 51, 10.1002/bdd.378 Xu, 2012, The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects, J Biomed Biotechnol., 2012, 10.1155/2012/386230